Latest News

(UroToday.com)  One of the fastest moving disease spaces in prostate cancer in metastatic castration sensitive prostate cancer. While androgen-deprivation therapy (ADT) alone was the standard treatment five years ago, now there are a number of treatment options which have been shown to improve overall survival, including docetaxel, abiraterone acetate, enzalutamide, and apalutamide. TITAN was the […]

(UroToday.com) There has been a proliferation in treatment options for patients with metastatic castration resistant prostate cancer (mCRPC) in the last 10 years. While the most commonly utilized approaches in prostate cancer are cytotoxic chemotherapy or target the androgen-axis, immune checkpoint inhibitors have revolutionized care of many solid organ malignancies. To data, immune checkpoint inhibitors have […]

(UroToday.com) PSMA-targeted PET/CT is superior to conventional imaging modalities to localize biochemically recurrent prostate cancer after local therapy, particularly in patients with low PSA (< 2 ng/mL) values. However, few studies have reported PSMA-targeted PET/CT accuracy compared to a pre-specified rigorous standard of truth including histopathology, correlative imaging, or treatment response in this population. The previously […]

Alicia Morgans: Hi, my name is Alicia Morgans and I’m a GU medical oncologist and associate professor of medicine at Northwestern University in Chicago in the United States. I’m so excited to have here with me today a good friend and colleague Dr. Karim Fizazi, who’s a GU medical oncologist and professor of oncology at […]

Alicia Morgans: Hi, my name is Alicia Morgans and I’m a GU medical oncologist and associate professor of medicine at Northwestern University in Chicago in the United States. I’m so excited to have here with me today, Dr. Srikala Sridhar. She is currently an associate professor of medicine, but recommended to be full professor of […]

(UroToday.com) The 2021 American Society of Clinical Oncology (ASCO) meeting included a session discussing the application of genomic testing treatments for patients with prostate cancer, including a presentation by Dr. Edward Schaeffer discussing the urology perspective of applying precision health to high-risk, localized disease.

(UroToday.com) The 2021 American Society of Clinical Oncology (ASCO) program included a session discussing the application of genomic testing treatments for patients with prostate cancer, including a presentation by Dr. Franklin Huang discussing the medical oncology perspective of the promise and limitations of precision health in metastatic disease.

– CABOMETYX in combination with OPDIVO demonstrated an objective response rate of 47.5% in a cohort of patients with certain histologies of advanced or metastatic nccRCC –– Data to be presented during the 2021 American Society of Clinical Oncology’s Annual Meeting –

(UroToday.com) The 2021 American Society of Clinical Oncology (ASCO) program included a session discussing the application of genomic testing treatments for patients with prostate cancer, including a presentation by Dr. Veda Giri discussing genomic medicine in prostate trials and treatments.

Data sourced from clinico-genomic database revealed lower rates of early genomic testing use and clinical trial enrollment among men of African ancestry compared to those of European ancestry San Francisco, CA (UroToday.com) — Foundation Medicine, Inc. and its collaborators announced the presentation of new data analyzing the genomic landscape, comprehensive genomic profiling (CGP) utilization and treatment […]